Dx & Vx Co

Dx & Vx Co Current Liabilities

The Current Liabilities of Dx & Vx Co (180400.KQ) as of Nov 5, 2026 is 1.29 B KRW. In the previous year, Current Liabilities was 6.58 B KRW — a change of -80.37% (lower).

Current Liabilities

1.29 BKRW

YoY

-80.37%

Last updated:

Current Liabilities of Dx & Vx Co is 2025 1.29 B KRW. Current Liabilities of Dx & Vx Co was 2024 6.58 B KRW. It decreases by -80.37% lower compared to the previous year.

The Dx & Vx Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
18.07 B KRW
Jan 1, 2019
6.15 B KRW
Jan 1, 2020
4.13 B KRW
Jan 1, 2021
5.63 B KRW
Jan 1, 2022
5.97 B KRW
Jan 1, 2023
5.76 B KRW
Jan 1, 2024
6.58 B KRW
Jan 1, 2025
1.29 B KRW
The Dx & Vx Co Current Liabilities history
YEARCurrent LiabilitiesYoY
1.29 BKRW-80.37%
6.58 BKRW+14.25%
5.76 BKRW-3.44%
5.97 BKRW+6.04%
5.63 BKRW+36.24%
4.13 BKRW-32.83%
6.15 BKRW-65.97%
18.07 BKRW-19.56%
22.46 BKRW+4,854.60%
453.27 MKRW-33.14%
677.94 MKRW+20.27%
563.69 MKRW-90.12%
5.70 BKRW+7.64%
5.30 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dx & Vx Co Stock analysis

What does Dx & Vx Co do? Dx & Vx Co., Ltd. generates revenue through the Molecular Diagnosis Business segment, which focuses on manufacturing and selling DNA chips, PCR chips, and related diagnostic reagents for molecular diagnosis. The company also produces enzymes and experimental reagents for biological research, targeting laboratories and healthcare facilities that require molecular diagnostic tools. Its products are sold to institutions involved in medical testing and research, leveraging the demand for advanced diagnostic solutions in healthcare. The company's revenue streams are derived from direct sales of these specialized products to the healthcare and research sectors. Dx & Vx Co., Ltd. operates within the molecular diagnostics market, offering DNA chips, PCR chips, and diagnostic reagents as core products. The company's focus on manufacturing and selling these items positions it as a provider of essential tools for molecular biology applications. Sales are directed toward laboratories and healthcare providers seeking to enhance their diagnostic capabilities through cutting-edge technology. The business model relies on consistent demand for molecular diagnostic equipment and reagents within the medical and research industries. Dx & Vx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dx & Vx Co stock

Current Liabilities of Dx & Vx Co is 1.29 B KRW in 2025.

Current Liabilities of Dx & Vx Co changed from 6.58 B KRW to 1.29 B KRW, representing a -80.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Dx & Vx Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Dx & Vx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Dx & Vx Co

All Key Metrics — Dx & Vx Co